Literature DB >> 9869512

Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer.

H M Kuerer1, L A Newman, B D Fornage, K Dhingra, K K Hunt, A U Buzdar, F C Ames, M I Ross, B W Feig, G N Hortobagyi, S E Singletary.   

Abstract

BACKGROUND: Induction chemotherapy has become the standard of care for patients with locally advanced breast cancer (LABC) and currently is being evaluated in prospective clinical trials in patients with earlier-stage disease. To better gauge the role of axillary lymph node dissection in patients with LABC this study was performed to assess initial axillary status on physical and ultrasound examination, axillary tumor downstaging following induction chemotherapy, and the accuracy of physical examination compared with axillary sonography in predicting which patients will have axillary lymph node metastases found on pathologic examination.
METHODS: Between 1992 and 1996, 147 consecutive patients with LABC were registered in a prospective trial of induction chemotherapy using 5-fluorouracil, doxorubicin, and cyclophosphamide. Physical and ultrasound examinations of the axilla were performed at diagnosis and after induction chemotherapy. Segmental resection with axillary lymph node dissection or modified radical mastectomy was performed, followed by postoperative chemotherapy and irradiation of the breast or chest wall and regional lymphatics.
RESULTS: Following induction chemotherapy, 43 (32%) of the 133 patients with clinically positive lymph nodes on initial examination had axillary tumor downstaging as assessed by physical and ultrasound examination. The sensitivity of axillary sonography in identifying axillary metastases was significantly higher than that of physical examination (62% vs. 45%, P=.012). The specificity of physical examination (84%) was higher than that of sonography (70%), but the difference did not reach statistical significance. Among the 55 patients in whom the findings of both physical and ultrasound examination of the axilla were negative following induction chemotherapy, 29 patients (53%) were found to have axillary lymph node metastases on pathologic examination of the axillary contents. However, 28 (97%) of these patients had either 1 to 3 positive lymph nodes or only micrometastases 2 to 5 mm in diameter.
CONCLUSIONS: Preoperative clinical assessment of the axilla by physical examination combined with ultrasound examination is not completely accurate in predicting metastases in patients with LABC following tumor downstaging. However, patients with negative findings on both physical and ultrasound examinations of the axilla may be potential candidates for omission of axillary dissection if the axilla will be irradiated because minimal axillary disease remains. Patients who have positive findings on preoperative physical or ultrasound examinations should receive axillary dissection to ensure local control. A prospective randomized trial of axillary dissection versus axillary radiotherapy in patients with a clinically negative axilla following induction chemotherapy is currently underway.

Entities:  

Mesh:

Year:  1998        PMID: 9869512     DOI: 10.1007/bf02303476

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

Review 1.  Dose-intensive chemotherapy for locally advanced breast cancer.

Authors:  J G Schrama; S Rodenhuis
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

Review 2.  Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations.

Authors:  Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-22       Impact factor: 9.236

3.  Can We Use MRI and US to Predict Axillary Node Response in Breast Cancer?

Authors:  Gary J Whitman
Journal:  Radiology       Date:  2019-08-13       Impact factor: 11.105

Review 4.  Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review.

Authors:  Jonathan Cools-Lartigue; Sarkis Meterissian
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

5.  Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).

Authors:  Elizabeth L Cureton; Christina Yau; Michael D Alvarado; Helen Krontiras; David W Ollila; Cheryl A Ewing; Sindy Monnier; Laura J Esserman
Journal:  Ann Surg Oncol       Date:  2014-05-01       Impact factor: 5.344

6.  Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.

Authors:  H M Kuerer; A A Sahin; K K Hunt; L A Newman; T M Breslin; F C Ames; M I Ross; A U Buzdar; G N Hortobagyi; S E Singletary
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

7.  Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy.

Authors:  Jacqueline S Jeruss; Lisa A Newman; Gregory D Ayers; Massimo Cristofanilli; Kristine R Broglio; Funda Meric-Bernstam; Min Yi; Jennifer F Waljee; Merrick I Ross; Kelly K Hunt
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

8.  Local and regional staging of invasive breast cancer with sonography: 25 years of practice at MD Anderson Cancer Center.

Authors:  Bruno D Fornage
Journal:  Oncologist       Date:  2013-12-05

9.  Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.

Authors:  J Schneider; S Gonzalez-Roces; M Pollán; R Lucas; A Tejerina; M Martin; A Alba
Journal:  Breast Cancer Res       Date:  2001-02-01       Impact factor: 6.466

10.  Sentinel lymph node biopsy alone after neoadjuvant chemotherapy in patients with initial cytology-proven axillary node metastasis.

Authors:  Ji Young Kim; Min Kuk Kim; Jeong Eon Lee; Yongsik Jung; Soo Youn Bae; Se Kyung Lee; Won Ho Kil; Seok Won Kim; Ku Sang Kim; Seok Jin Nam; Sehwan Han
Journal:  J Breast Cancer       Date:  2015-03-27       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.